A double blind, multinational, multicentre, placebo controlled 10-week study assessing the efficacy and safety of F2695 SR flexible dose (75, 100 mg/day) in the treatment of patients with major depression
A double blind, multinational, multicentre, placebo controlled 10-week study assessing the efficacy and safety of F2695 SR flexible dose (75, 100 mg/day) in the treatment of patients with major depression
A double blind, multinational, multicentre, placebo controlled 10-week study assessing the efficacy and safety of F2695 SR flexible dose (75, 100 mg/day) in the treatment of patients with major depression
Status
Status :
Completed
Type of study
Phase II
Min. Age
18
Years old
Max. Age
70
Years old
Gender
All
Therapeutic area :
Mental Health
Disease :
Depression
Study medication :
F2695
Phase :
Phase II
Start Date :
13 December 2006
End date :
22 October 2007
Study ID :
F02695 LP 202
EudraCT/CTIS number :
2006-002404-34
Send by email